Trevi Therapeutics, Inc.
NASDAQ:TRVIBiotechnology
+$0.43 today
- Market cap
- $1.93B
- Beta
- 1.05
- P/E (TTM)
- -53.6
- EPS (TTM)
- -$0.31
Volume 2.02M
Average 1.44M
TRVI Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Trevi Therapeutics, Inc.NASDAQ: TRVI
Selling, General & Admin · Q3 FY2026 · quarter ended Sep 2026
Selling, general & admin growth accelerates
Q3 FY2026 selling, general & admin of $5.42M rose 41.5% year over year, ahead of the +34.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at +16.3% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 10 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +30.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $5.42M+1.2% QoQ
- Last fiscal yearDec 2025
- $15.85M+30.5% YoY
- LTMSep 2026
- $19.78M+34.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +41.5% | -100.0% | -141.5 pp |
| 1 year | +30.5% | -100.0% | -130.5 pp |
| 3-year CAGR | +16.3% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 15.85M USD
- Year-over-year change
- +30.5%
- 4-year CAGR
- +13.7%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.85M | +30.5% |
| FY2024 | 2024-12-31 | 12.15M | +18.6% |
| FY2023 | 2023-12-31 | 10.24M | +1.7% |
| FY2022 | 2022-12-31 | 10.07M | +6.1% |
| FY2021 | 2021-12-31 | 9.49M | — |
Selling, General & Admin vs competitors
How TRVI compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +34.5% is the 6th highest of 9, against a peer median of +38.3%.
- Over three fiscal years its annual growth of +16.3% compares with a peer median of +59.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $646.09M USD | +23.5% | +14.1% | 53.7% | |
| LTM Jun 2026 | $192.66M USD | +74.7% | +69.3% | 42.7% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 48.85M SEK | +20.6% | +21.9% | 3673.4% |
| LTM Mar 2026 | $37.58M USD | +103.1% | +3.2% | 34.2% | |
| LTM Mar 2026 | $34.94M USD | -61.3% | — | 50.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $34.27M USD | +37.9% | +181.0% | 171.4% |
UPBUpstream Bio, Inc. | LTM Mar 2026 | $27.71M USD | +38.6% | +59.9% | 834.2% |
| LTM Mar 2026 | $23.09M USD | +106.1% | +61.1% | — | |
| LTM Sep 2026 | $19.78M USD | +34.5% | +16.3% | — | |
| Peer median (excluding TRVI) | — | +38.3% | +59.9% | 53.7% | |
Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 22.98M | 19.83M | 23.68M | 39.38M | 33.48M |
| Selling, General & Admin | 9.49M | 10.07M | 10.24M | 12.15M | 15.85M |
| Operating Expenses | 32.48M | 29.91M | 33.92M | 51.52M | 49.33M |
| Depreciation & Amortization | 50K | 43K | 123K | 147K | 144K |
| EBITDA | (32.71M) | (27.98M) | (28.58M) | (47.79M) | (42.68M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (32.48M) | (29.91M) | (33.92M) | (51.52M) | (49.33M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 10K | 1.74M | 4.75M | 3.6M | 6.54M |
| Interest Expense | 1.2M | 780K | 391K | 4K | 0 |
| Other Income / Expenses | (1.49M) | 719K | 4.83M | 3.58M | 6.51M |
| Income Before Tax | (33.96M) | (29.19M) | (29.1M) | (47.94M) | (42.82M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (21K) | (36K) | (32K) | (30K) | (64K) |
| Net Income | (33.94M) | (29.15M) | (29.07M) | (47.91M) | (42.76M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.49) | (0.45) | (0.29) | (0.47) | (0.29) |
| EPS (Diluted) | (1.49) | (0.45) | (0.29) | (0.47) | (0.29) |
| Weighted Avg Shares | 22.84M | 64.54M | 99.03M | 101.04M | 145.1M |
| Weighted Avg Shares (Diluted) | 22.84M | 64.54M | 99.03M | 101.04M | 145.1M |
Trevi Therapeutics, Inc.
NASDAQ:TRVI
Intrinsic Alpha fair value
Locked
Current Price
$13.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.